Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis

Objective: To examine associations between the composition of the vaginal microbiota and genitourinary menopausal symptoms, serum estrogen, and vaginal glycogen. Methods: For this cross-sectional study, 88 women aged 40 to 62 years, enrolled in a hot flash treatment trial, provided vaginal swabs and a blood sample at enrollment. Bacterial communities were characterized using 16S rRNA PCR and deep sequencing targeting the V3-V4 region. Quantities of Lactobacillus crispatus and Lactobacillus iners were measured using qPCR. Self-reported genitourinary symptoms included: presence and severity of individual symptoms and identification of most bothersome symptom. Glycogen was measured fluorometrically in swab eluate. Serum estradiol (E2) and estrone (E1) were measured by liquid chromatography/mass spectrometry. Associations between bacteria, symptoms, glycogen, and serum estrogens were tested by linear regression or Wilcoxon signed-rank test, adjusted for multiple comparisons. Comparisons between groups used Kruskall-Wallis or Fisher's exact test. Results: Of the 88 women, 33 (38%) had a majority of Lactobacillus species, whereas 58 (66%) had any Lactobacillus detected. Over half (53%) reported at least one vulvovaginal symptom (most commonly dryness), but symptoms were not associated with the presence of Lactobacillus species. Women with Lactobacillus-dominant communities had higher unconjugated serum estrone, but no difference in vaginal glycogen levels, compared with those with non-Lactobacillus-dominant communities. Higher serum E2 and E1 were not associated with either higher vaginal glycogen or detection of individual genera. Conclusions: Presence of Lactobacillus-dominant vaginal microbiota was not associated with fewer vulvovaginal symptoms. Serum estrone was higher in women with Lactobacillus dominance, but vaginal-free glycogen was not associated with composition of the vaginal microbiota.

[1]  E. Golub,et al.  Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women , 2015, Menopause.

[2]  M. Dibonaventura,et al.  The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. , 2015, Journal of women's health.

[3]  Candace S. Brown,et al.  The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. , 2000, Journal of sex & marital therapy.

[4]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[5]  Jeanne M. Marrazzo,et al.  More Than Meets the Eye: Associations of Vaginal Bacteria with Gram Stain Morphotypes Using Molecular Phylogenetic Analysis , 2013, PloS one.

[6]  F. Sánchez-Marín,et al.  The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women. , 2004, Maturitas.

[7]  J. Manson,et al.  Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. , 2014, JAMA internal medicine.

[8]  N. Santoro,et al.  Prevalence and impact of vaginal symptoms among postmenopausal women. , 2009, The journal of sexual medicine.

[9]  S. Hillier,et al.  Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  I. Blair,et al.  Ultra-high sensitivity analysis of estrogens for special populations in serum and plasma by liquid chromatography–mass spectrometry: Assay considerations and suggested practices , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  Alan R. Dabney,et al.  Diet Complexity and Estrogen Receptor β Status Affect the Composition of the Murine Intestinal Microbiota , 2013, Applied and Environmental Microbiology.

[12]  Daniel Raftery,et al.  Metabolic Signatures of Bacterial Vaginosis , 2015, mBio.

[13]  G. Bachmann,et al.  Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally , 2009, Menopause.

[14]  T. Hope,et al.  Glycogen Levels in Undiluted Genital Fluid and Their Relationship to Vaginal pH, Estrogen, and Progesterone , 2016, PloS one.

[15]  A. LaCroix,et al.  Methods for the design of vasomotor symptom trials: the Menopausal Strategies Finding Lasting Answers to Symptoms and Health network , 2014, Menopause.

[16]  T. Iannicelli,et al.  Prevalence of Bacterial Vaginosis and Vaginal Flora Changes in Peri- and Postmenopausal Women , 2002, Journal of Clinical Microbiology.

[17]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[18]  M. J. Minkin,et al.  Prevalence of postmenopausal symptoms in North America and Europe , 2015, Menopause.

[19]  S. K. Van Den Eeden,et al.  Predictors of impact of vaginal symptoms in postmenopausal women , 2016, Menopause.

[20]  L. Forney,et al.  Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis , 2016, Scientific Reports.

[21]  Rui Chen,et al.  Qualitative and semiquantitative analysis of Lactobacillus species in the vaginas of healthy fertile and postmenopausal Chinese women. , 2012, Journal of medical microbiology.

[22]  Jeanne M. Marrazzo,et al.  Bacterial Communities in Women with Bacterial Vaginosis: High Resolution Phylogenetic Analyses Reveal Relationships of Microbiota to Clinical Criteria , 2012, PloS one.

[23]  G. Bachmann,et al.  Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women , 2009, Menopause.

[24]  G. Davila,et al.  Are women with urogenital atrophy symptomatic? , 2003, American journal of obstetrics and gynecology.

[25]  Jacques Ravel,et al.  Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy , 2018, Menopause.

[26]  J. Marrazzo,et al.  Temporal Variability of Human Vaginal Bacteria and Relationship with Bacterial Vaginosis , 2010, PloS one.

[27]  R. Ness,et al.  Identification of novel microbes associated with pelvic inflammatory disease and infertility , 2016, Sexually Transmitted Infections.

[28]  P. Ganz,et al.  Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. , 1999, Climacteric : the journal of the International Menopause Society.

[29]  J. Marrazzo,et al.  Molecular identification of bacteria associated with bacterial vaginosis. , 2005, The New England journal of medicine.

[30]  J. Marrazzo,et al.  Changes in Vaginal Bacterial Concentrations with Intravaginal Metronidazole Therapy for Bacterial Vaginosis as Assessed by Quantitative PCR , 2009, Journal of Clinical Microbiology.

[31]  B. Hamaker,et al.  Human α-amylase present in lower-genital-tract mucosal fluid processes glycogen to support vaginal colonization by Lactobacillus. , 2014, The Journal of infectious diseases.

[32]  Jean M. Macklaim,et al.  Vaginal Microbiome and Epithelial Gene Array in Post-Menopausal Women with Moderate to Severe Dryness , 2011, PloS one.

[33]  S. Ahrné,et al.  The Lactobacillus flora in vagina and rectum of fertile and postmenopausal healthy Swedish women , 2011, BMC women's health.

[34]  G. Guyatt,et al.  A menopause-specific quality of life questionnaire: development and psychometric properties. , 1996, Maturitas.